Psychemedics (Psychemedics) Debt-to-Equity

: 0.34 (As of Dec. 2023)

View and export this data going back to 1987. Start your Free Trial

Psychemedics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.35 Mil. Psychemedics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.95 Mil. Psychemedics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $6.67 Mil. Psychemedics's debt to equity for the quarter that ended in Dec. 2023 was 0.34.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Psychemedics's Debt-to-Equity or its related term are showing as below:

PMD' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09 Med: 0.35 Max: 0.71
Current: 0.34

During the past 13 years, the highest Debt-to-Equity Ratio of Psychemedics was 0.71. The lowest was 0.09. And the median was 0.35.

PMD's Debt-to-Equity is ranked worse than
58.38% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs PMD: 0.34

Psychemedics Debt-to-Equity Historical Data

The historical data trend for Psychemedics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psychemedics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.36

0.71

0.42

0.33

0.34

Psychemedics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.33	0.33	0.33	0.36	0.34

Competitive Comparison

For the Diagnostics & Research subindustry, Psychemedics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Psychemedics Debt-to-Equity Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Psychemedics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Psychemedics's Debt-to-Equity falls into.

Psychemedics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Psychemedics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.353	+	0.945)	/	6.672
	=	0.34

Psychemedics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.353	+	0.945)	/	6.672
	=	0.34

Psychemedics (NAS:PMD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Psychemedics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Psychemedics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Psychemedics (Psychemedics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Psychemedics Corp (NAS:PMD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

289 Great Road, Suite 200, Acton, MA, USA, 01720

Website

https://www.psychemedics.com

Psychemedics Corp is engaged in providing testing services for the detection of drugs of abuse through the analysis of hair samples. The company operates through a single segment of drug testing services which include training for the collection of samples and storage of positive samples for its customers for an agreed-upon fee per unit testing of samples. The testing methods of the company utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. Geographically it generates the majority of its revenue from the United States.

Executives

Shannon Shoemaker	officer: Chief Revenue Officer	289 GREAT ROAD, SUITE 200, ACTON MA 01720
Charles M Doucot	officer: Executive Vice President	289 GREAT ROAD, SUITE 200, ACTON MA 01720
Andrew Reynolds	director	C/O FLEETMATICS, 1100 WINTER STREET, 4TH FL, WALTHAM MA 02451
Brian Hullinger	director, officer: President & CEO	289 GREAT ROAD, SUITE 200, ACTON MA 01720
Robyn C Davis	director	ONE WALLINGFORD ROAD, MARBLEHEAD MA 01945
Michael Weisenhoff	other: Assistant Controller	289 GREAT ROAD, SUITE 200, ACTON MA 01720
Michael I Schaffer	officer: VP of Laboratory Operations	C/O PAYCHEMEDICS CORP, 1280 MASSACHUSETTS AVE STE 200, CAMBRIDGE MA 02138
William B. Norris	other: Assistant Controller	289 GREAT ROAD, SUITE 200, ACTON MA 01720
Darius G Nevin	other: See Footnote 1	C/O WCI COMMUNITIES, INC., 24301 WALDEN CENTER DRIVE, BONITA SPRINGS FL 34134
Peter H Kamin	10 percent owner	2720 DONALD ROSS ROAD, #311, PALM BEACH GARDENS FL 33410
Andrew Limbek	officer: Vice President & Controller	289 GREAT ROAD, SUITE 200, ACTON MA 01720
Fred J Weinert	director	330 E MAIN ST, BARRINGTON IL 60620
Kubacki Raymond C Jr	director, officer: Chairman, CEO & President	125 NAGOG PARK, ACTON MA 01720
A Clinton Allen	director, officer: Chairman	1280 MASSACHUSETTS AVE STE 200, CAMBRIDGE MA 02138
Neil Lerner	officer: VP - Finance	C/O PSYCHEMEDICS CORPORATION, 125 NAGOG PARK, ACTON MA 01720